Table 1. Subject Demographics and Baseline Characteristics.
| PD Subjects (n = 94) | ||
|---|---|---|
| Age (years) | Mean (SD) | 59.3 (9.2) |
| Gender: n (%) | Male | 72 (76.6) |
| Female | 22 (23.4) | |
| Disease duration (years) | Mean (SD) | 3.0 (2.7) |
| Median (Range) | 2.5 (0.4–14.3) | |
| Functional Parameters | ||
| MMSE score | 28.7 (1.2) | |
| BDI-II score | 4.9 (3.9) | |
| Estimated FS IQ | 111.6 (9.8) | |
| Education (years) | 16.4 (3.1) | |
| Total UPDRS score (Off) | 29.8 (10.3) | |
| UPDRS Motor score (Off) | 20.4 (6.8) | |
| UPDRS ADL score (Off) | 8.9 (4.3) | |
| UPDRS Mentation score (Off) | 0.9 (1.0) | |
| Medication Usage | ||
| Levodopa (# of subjects (percent)) | 46 (48.9) | |
| Dopamine Agonist* (# of subjects (percent)) | 65 (69.1) | |
| Selegiline (# of subjects (percent)) | 15 (39.5) | |
| Other (# of subjects (percent))^ | 2 (5.2) |
Data presented as mean ± SD, unless otherwise noted.
*Dopamine agonists included pramipexole, ropinirole, pergolide and bromocriptine.
^Other medications included amantadine, trihexyphenidyl, and benztropine.